ONI Names Sharon Krumm, PhD, RN, Editor of Oncology Nursing

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

MELVILLE, New York-The publishers of ONI are pleased to announce that Sharon K. Krumm, PhD, RN, will serve as Editor of Oncology Nursing. Dr. Krumm earned her bachelor of science in nursing from the University of Missouri School of Nursing, Columbia, and her MS and PhD from the University of Missouri.

MELVILLE, New York—The publishers of ONI are pleased to announce that Sharon K. Krumm, PhD, RN, will serve as Editor of Oncology Nursing. Dr. Krumm earned her bachelor of science in nursing from the University of Missouri School of Nursing, Columbia, and her MS and PhD from the University of Missouri.

Since 1996, she has been administrator and director of nursing at The Johns Hopkins Oncology Center, Baltimore. She is also assistant professor at The Johns Hopkins University Schools of Medicine and Nursing. Previously, she was director of nursing at the University of Missouri, Ellis Fischel Cancer Center. She joined Johns Hopkins in 1988 as director of nursing.

Dr. Krumm serves on the Board of Trustees of the American Cancer Society Mid-Atlantic Division. She has extensive research experience and is currently principal investigator for a study evaluating Johns Hopkins’ inpatient/outpatient care continuum program. She is the author, coauthor, or editor of 30 journal articles or abstracts and seven books.

Dr. Krumm brings to ONI a wealth of knowledge in the oncology nursing field and will be actively involved in selecting material specifically of interest to oncology nurses.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video